<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Dermata Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/dermata-therapeutics-inc</link>
<description>Latest news and press releases for Dermata Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/dermata-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355f5b78dffbe2df0ed8f5.webp</url>
<title>Dermata Therapeutics Inc</title>
<link>https://6ix.com/company/dermata-therapeutics-inc</link>
</image>
<item>
<title>Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 </title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-provides-corporate-update-and-reports-financial-results-for-the-year-ended-2025</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-provides-corporate-update-and-reports-financial-results-for-the-year-ended-2025</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skincare products under the brand name Tome -- Dermata plans to</description>
</item>
<item>
<title>Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-announces-appointment-of-kyra-peckaitis-as-vice-president-marketing-13</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-announces-appointment-of-kyra-peckaitis-as-vice-president-marketing-13</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand - SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / Dermata</description>
</item>
<item>
<title>Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-receives-notice-grant-patent-130500010</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-receives-notice-grant-patent-130500010</guid>
<pubDate>Tue, 20 Jan 2026 13:05:00 GMT</pubDate>
<description>This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acne Dermata expects to launch a new once-weekly, over-the-counter (OTC) acne treatment system, incorporating ...</description>
</item>
<item>
<title>Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-announces-closing-12-210500982</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-announces-closing-12-210500982</guid>
<pubDate>Mon, 29 Dec 2025 21:05:00 GMT</pubDate>
<description>$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 29, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," ...</description>
</item>
<item>
<title>Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-announces-12-4-130000740</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-announces-12-4-130000740</guid>
<pubDate>Wed, 24 Dec 2025 13:00:00 GMT</pubDate>
<description>$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 24, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," ...</description>
</item>
<item>
<title>A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/realm-skincare-coming-dermata-teases-130000687</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/realm-skincare-coming-dermata-teases-130000687</guid>
<pubDate>Thu, 04 Dec 2025 13:00:00 GMT</pubDate>
<description>SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that it will soon reveal its new brand name ...</description>
</item>
<item>
<title>Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-provides-corporate-reports-210500737</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-provides-corporate-reports-210500737</guid>
<pubDate>Fri, 14 Nov 2025 21:05:00 GMT</pubDate>
<description>- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments - - Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongilla technology, in the middle of 2026 - SAN DIEGO, ...</description>
</item>
<item>
<title>Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-announces-acceptance-patent-application-120000172</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-announces-acceptance-patent-application-120000172</guid>
<pubDate>Thu, 02 Oct 2025 12:00:00 GMT</pubDate>
<description>- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne - - Dermata expects to launch a new once-weekly, Over-the-Counter (OTC) pharmaceutical acne kit, incorporating ...</description>
</item>
<item>
<title>Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-announces-presentation-abstract-050000917</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-announces-presentation-abstract-050000917</guid>
<pubDate>Wed, 17 Sep 2025 05:00:00 GMT</pubDate>
<description>- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne - SAN DIEGO, CA / ACCESS Newswire / September 17, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ...</description>
</item>
<item>
<title>Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-present-life-sciences-123500809</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-present-life-sciences-123500809</guid>
<pubDate>Tue, 16 Sep 2025 12:35:00 GMT</pubDate>
<description>Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.comSAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com San Diego, CA, September 16, 2025 -- Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRM</description>
</item>
<item>
<title>Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-announces-strategic-pivot-120000843</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-announces-strategic-pivot-120000843</guid>
<pubDate>Wed, 10 Sep 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the ...</description>
</item>
<item>
<title>Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments </title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-announces-strategic-pivot-to-over-the-counter-skin-care-treatments</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-announces-strategic-pivot-to-over-the-counter-skin-care-treatments</guid>
<pubDate>Wed, 10 Sep 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven</description>
</item>
<item>
<title>Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-provides-corporate-reports-210000044</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-provides-corporate-reports-210000044</guid>
<pubDate>Wed, 13 Aug 2025 21:00:00 GMT</pubDate>
<description>- Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial- - Raised $8.8 million in gross proceeds from a private placement and warrant inducement financings during the ...</description>
</item>
<item>
<title>Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-receives-notice-grant-australian-120000806</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-receives-notice-grant-australian-120000806</guid>
<pubDate>Tue, 08 Jul 2025 12:00:00 GMT</pubDate>
<description>- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 ...</description>
</item>
<item>
<title>Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-provides-corporate-reports-130000675</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-provides-corporate-reports-130000675</guid>
<pubDate>Wed, 14 May 2025 13:00:00 GMT</pubDate>
<description>- Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints - - Dermata entered into a Clinical Trial Collaboration Agreement with Revance ...</description>
</item>
<item>
<title>Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-xyngari-tm-phase-3-123000297</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-xyngari-tm-phase-3-123000297</guid>
<pubDate>Tue, 15 Apr 2025 12:30:00 GMT</pubDate>
<description>- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly ...</description>
</item>
<item>
<title>Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-announces-exercise-warrants-001500364</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-announces-exercise-warrants-001500364</guid>
<pubDate>Fri, 28 Mar 2025 00:15:00 GMT</pubDate>
<description>SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, ...</description>
</item>
<item>
<title>BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/breaking-dermatas-xyngari-phase-3-120000020</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/breaking-dermatas-xyngari-phase-3-120000020</guid>
<pubDate>Thu, 27 Mar 2025 12:00:00 GMT</pubDate>
<description>Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARITM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events</description>
</item>
<item>
<title>Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-provides-corporate-reports-201600200</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-therapeutics-provides-corporate-reports-201600200</guid>
<pubDate>Mon, 17 Mar 2025 20:16:00 GMT</pubDate>
<description>- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 - - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance ...</description>
</item>
<item>
<title>Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne</title>
<link>https://6ix.com/company/dermata-therapeutics-inc/news/dermata-announces-last-patient-completes-130300327</link>
<guid isPermaLink="true">https://6ix.com/company/dermata-therapeutics-inc/news/dermata-announces-last-patient-completes-130300327</guid>
<pubDate>Tue, 04 Mar 2025 13:03:00 GMT</pubDate>
<description>Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the last patient has completed their last visit in the Company's first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The Company remains on track to annou</description>
</item>
</channel>
</rss>